Human KRT10(Keratin 10) ELISA Kit

Description: This is Double-antibody Sandwich Enzyme-linked immunosorbent assay for detection of Human Keratin 10 (KRT10) in serum, plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids.

Description: This is Double-antibody Sandwich Enzyme-linked immunosorbent assay for detection of Human Keratin 10 (KRT10) in serum, plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids.

Description: This is Double-antibody Sandwich Enzyme-linked immunosorbent assay for detection of Human Keratin 10 (KRT10) in serum, plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids.

Description: This is Double-antibody Sandwich Enzyme-linked immunosorbent assay for detection of Human Keratin 10 (KRT10) in serum, plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids.

Description: Enzyme-linked immunosorbent assay based on the Double-antibody Sandwich method for detection of Human Keratin 10 (KRT10) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids with no significant corss-reactivity with analogues from other species.

Description: A sandwich ELISA kit for detection of Keratin 10 from Human in samples from blood, serum, plasma, cell culture fluid and other biological fluids.

Description: Recombinant Human Keratin 10 expressed in: E.coli

Description: Recombinant Rat Keratin 10 expressed in: E.coli

Description: A Rabbit polyclonal antibody against Human Keratin 10 (KRT10)

Description: Method of detection: Double Antibody, Sandwich ELISA;Reacts with: Homo sapiens;Sensitivity: 9.375pg/ml

Description: Recombinant Human Keratin, type I cytoskeletal 10(KRT10) expressed in E.coli

Description: Recombinant Human KeRatin, type I cytoskeletal 10(KRT10),partial expressed in Yeast

Description: A Rabbit polyclonal antibody against Human Keratin 10 (KRT10). This antibody is labeled with APC.

Description: A Rabbit polyclonal antibody against Human Keratin 10 (KRT10). This antibody is labeled with Biotin.

Description: A Rabbit polyclonal antibody against Human Keratin 10 (KRT10). This antibody is labeled with Cy3.

Description: A Rabbit polyclonal antibody against Human Keratin 10 (KRT10). This antibody is labeled with FITC.

Description: A Rabbit polyclonal antibody against Human Keratin 10 (KRT10). This antibody is labeled with HRP.

Description: A Rabbit polyclonal antibody against Human Keratin 10 (KRT10). This antibody is labeled with PE.

Description: A Rabbit polyclonal antibody against Rat Keratin 10 (KRT10)

Description: Quantitative sandwich ELISA for measuring Human Keratin, type I cytoskeletal 10 (KRT10) in samples from cell culture supernatants, serum, whole blood, plasma and other biological fluids.

Description: Quantitative sandwich ELISA for measuring Human Keratin, type I cytoskeletal 10 (KRT10) in samples from cell culture supernatants, serum, whole blood, plasma and other biological fluids.

Description: Quantitative sandwich ELISA for measuring Human Keratin, type I cytoskeletal 10 (KRT10) in samples from cell culture supernatants, serum, whole blood, plasma and other biological fluids.

Description: A sandwich ELISA kit for quantitative measurement of Human KRT10 (Keratin, Type I Cytoskeletal 10) in samples from Serum, Plasma, Cell supernatant

Description: Mouse monoclonal Keratin 10 antibody

Description: A Rabbit polyclonal antibody against Human Keratin 10 (KRT10). This antibody is labeled with APC-Cy7.

Description: A Rabbit polyclonal antibody against Rat Keratin 10 (KRT10). This antibody is labeled with APC.

Description: A Rabbit polyclonal antibody against Rat Keratin 10 (KRT10). This antibody is labeled with Biotin.

Description: A Rabbit polyclonal antibody against Rat Keratin 10 (KRT10). This antibody is labeled with Cy3.

Description: A Rabbit polyclonal antibody against Rat Keratin 10 (KRT10). This antibody is labeled with FITC.

Description: A Rabbit polyclonal antibody against Rat Keratin 10 (KRT10). This antibody is labeled with HRP.

Description: A Rabbit polyclonal antibody against Rat Keratin 10 (KRT10). This antibody is labeled with PE.

Description: A sandwich CLIA kit for quantitative measurement of Human KRT10 (Keratin, Type I Cytoskeletal 10) in samples from Serum, Plasma, Cell supernatant

Description: A Rabbit polyclonal antibody against Rat Keratin 10 (KRT10). This antibody is labeled with APC-Cy7.

Description: CK10 is expressed in all suprabasal layers of the epidermis. In the epidermis, expression of CK10 strictly parallels the extent of differentiation; it is absent in the basal layer, appears in the first suprabasal layers and increases in concentration towards the granular layer. However, CK10 is rarely detected in early stages of vulvar squamous carcinomas (tumors less than 2 cm, clinical stage I) regardless of the tumor grade. In larger and more advanced tumors (greater than 2 cm, clinical stages II and III), CK10 is detected very frequently. Expression of CK10 is related to maturation of malignant keratinocytes, being preferentially detected in more-differentiated parts.

Description: CK10 is expressed in all suprabasal layers of the epidermis. In the epidermis, expression of CK10 strictly parallels the extent of differentiation; it is absent in the basal layer, appears in the first suprabasal layers and increases in concentration towards the granular layer. However, CK10 is rarely detected in early stages of vulvar squamous carcinomas (tumors less than 2 cm, clinical stage I) regardless of the tumor grade. In larger and more advanced tumors (greater than 2 cm, clinical stages II and III), CK10 is detected very frequently. Expression of CK10 is related to maturation of malignant keratinocytes, being preferentially detected in more-differentiated parts.

Description: CK10 is expressed in all suprabasal layers of the epidermis. In the epidermis, expression of CK10 strictly parallels the extent of differentiation; it is absent in the basal layer, appears in the first suprabasal layers and increases in concentration towards the granular layer. However, CK10 is rarely detected in early stages of vulvar squamous carcinomas (tumors less than 2 cm, clinical stage I) regardless of the tumor grade. In larger and more advanced tumors (greater than 2 cm, clinical stages II and III), CK10 is detected very frequently. Expression of CK10 is related to maturation of malignant keratinocytes, being preferentially detected in more-differentiated parts.

Description: CK10 is expressed in all suprabasal layers of the epidermis. In the epidermis, expression of CK10 strictly parallels the extent of differentiation; it is absent in the basal layer, appears in the first suprabasal layers and increases in concentration towards the granular layer. However, CK10 is rarely detected in early stages of vulvar squamous carcinomas (tumors less than 2 cm, clinical stage I) regardless of the tumor grade. In larger and more advanced tumors (greater than 2 cm, clinical stages II and III), CK10 is detected very frequently. Expression of CK10 is related to maturation of malignant keratinocytes, being preferentially detected in more-differentiated parts.

Description: This mAb recognizes a protein of 56.5 kDa, identified as cytokeratin 10 (CK10). CK10 is expressed in all suprabasal layers of the epidermis. In the epidermis, expression of CK10 strictly parallels the extent of differentiation; it is absent in the basal layer, appears in the first suprabasal layers and increases in concentration towards the granular layer. However, CK10 is rarely detected in early stages of vulvar squamous carcinomas (tumors less than 2 cm, clinical stage I) regardless of the tumor grade. In larger and more advanced tumors (greater than 2 cm, clinical stages II and III), CK10 is detected very frequently. Expression of CK10 is related to maturation of malignant keratinocytes, being preferentially detected in more-differentiated parts.

Description: This mAb recognizes a protein of 56.5 kDa, identified as cytokeratin 10 (CK10). CK10 is expressed in all suprabasal layers of the epidermis. In the epidermis, expression of CK10 strictly parallels the extent of differentiation; it is absent in the basal layer, appears in the first suprabasal layers and increases in concentration towards the granular layer. However, CK10 is rarely detected in early stages of vulvar squamous carcinomas (tumors less than 2 cm, clinical stage I) regardless of the tumor grade. In larger and more advanced tumors (greater than 2 cm, clinical stages II and III), CK10 is detected very frequently. Expression of CK10 is related to maturation of malignant keratinocytes, being preferentially detected in more-differentiated parts.

Description: This mAb recognizes a protein of 56.5 kDa, identified as cytokeratin 10 (CK10). CK10 is expressed in all suprabasal layers of the epidermis. In the epidermis, expression of CK10 strictly parallels the extent of differentiation; it is absent in the basal layer, appears in the first suprabasal layers and increases in concentration towards the granular layer. However, CK10 is rarely detected in early stages of vulvar squamous carcinomas (tumors less than 2 cm, clinical stage I) regardless of the tumor grade. In larger and more advanced tumors (greater than 2 cm, clinical stages II and III), CK10 is detected very frequently. Expression of CK10 is related to maturation of malignant keratinocytes, being preferentially detected in more-differentiated parts.

Description: This mAb recognizes a protein of 56.5 kDa, identified as cytokeratin 10 (CK10). CK10 is expressed in all suprabasal layers of the epidermis. In the epidermis, expression of CK10 strictly parallels the extent of differentiation; it is absent in the basal layer, appears in the first suprabasal layers and increases in concentration towards the granular layer. However, CK10 is rarely detected in early stages of vulvar squamous carcinomas (tumors less than 2 cm, clinical stage I) regardless of the tumor grade. In larger and more advanced tumors (greater than 2 cm, clinical stages II and III), CK10 is detected very frequently. Expression of CK10 is related to maturation of malignant keratinocytes, being preferentially detected in more-differentiated parts.

Description: This mAb recognizes a protein of 56.5kDa, identified as cytokeratin 10 (CK10). CK10 is expressed in all suprabasal layers of the epidermis. In the epidermis, expression of CK10 strictly parallels the extent of differentiation; it is absent in the basal layer, appears in the first suprabasal layers and increases in concentration towards the granular layer. However, CK10 is rarely detected in early stages of vulvar squamous carcinomas (tumors less than 2 cm, clinical stage I) regardless of the tumor grade. In larger and more advanced tumors (greater than 2 cm, clinical stages II and III), CK10 is detected very frequently. Expression of CK10 is related to maturation of malignant keratinocytes, being preferentially detected in more-differentiated parts.

Description: This mAb recognizes a protein of 56.5kDa, identified as cytokeratin 10 (CK10). CK10 is expressed in all suprabasal layers of the epidermis. In the epidermis, expression of CK10 strictly parallels the extent of differentiation; it is absent in the basal layer, appears in the first suprabasal layers and increases in concentration towards the granular layer. However, CK10 is rarely detected in early stages of vulvar squamous carcinomas (tumors less than 2 cm, clinical stage I) regardless of the tumor grade. In larger and more advanced tumors (greater than 2 cm, clinical stages II and III), CK10 is detected very frequently. Expression of CK10 is related to maturation of malignant keratinocytes, being preferentially detected in more-differentiated parts.

Description: This mAb recognizes a protein of 56.5kDa, identified as cytokeratin 10 (CK10). CK10 is expressed in all suprabasal layers of the epidermis. In the epidermis, expression of CK10 strictly parallels the extent of differentiation; it is absent in the basal layer, appears in the first suprabasal layers and increases in concentration towards the granular layer. However, CK10 is rarely detected in early stages of vulvar squamous carcinomas (tumors less than 2 cm, clinical stage I) regardless of the tumor grade. In larger and more advanced tumors (greater than 2 cm, clinical stages II and III), CK10 is detected very frequently. Expression of CK10 is related to maturation of malignant keratinocytes, being preferentially detected in more-differentiated parts.

Description: This mAb recognizes a protein of 56.5kDa, identified as cytokeratin 10 (CK10). CK10 is expressed in all suprabasal layers of the epidermis. In the epidermis, expression of CK10 strictly parallels the extent of differentiation; it is absent in the basal layer, appears in the first suprabasal layers and increases in concentration towards the granular layer. However, CK10 is rarely detected in early stages of vulvar squamous carcinomas (tumors less than 2 cm, clinical stage I) regardless of the tumor grade. In larger and more advanced tumors (greater than 2 cm, clinical stages II and III), CK10 is detected very frequently. Expression of CK10 is related to maturation of malignant keratinocytes, being preferentially detected in more-differentiated parts.

Description: Keratin-10 is a member of the type I (acidic) cytokeratin family, which belongs to the superfamily of intermediate filament (IF) proteins. Keratins are heteropolymeric structural proteins which form the intermediate filament. These filaments, along with actin microfilaments and microtubules, compose the cytoskeleton of epithelial cells. Mutations in this gene are associated with epidermolytic hyperkeratosis. [Wiki]

Description: Keratin-10 is a member of the type I (acidic) cytokeratin family, which belongs to the superfamily of intermediate filament (IF) proteins. Keratins are heteropolymeric structural proteins which form the intermediate filament. These filaments, along with actin microfilaments and microtubules, compose the cytoskeleton of epithelial cells. Mutations in this gene are associated with epidermolytic hyperkeratosis. [Wiki]

Description: Keratin-10 is a member of the type I (acidic) cytokeratin family, which belongs to the superfamily of intermediate filament (IF) proteins. Keratins are heteropolymeric structural proteins which form the intermediate filament. These filaments, along with actin microfilaments and microtubules, compose the cytoskeleton of epithelial cells. Mutations in this gene are associated with epidermolytic hyperkeratosis. [Wiki]

Description: This mAb recognizes a protein of 56.5kDa, identified as cytokeratin 10 (CK10). CK10 is expressed in all suprabasal layers of the epidermis. In the epidermis, expression of CK10 strictly parallels the extent of differentiation; it is absent in the basal layer, appears in the first suprabasal layers and increases in concentration towards the granular layer. However, CK10 is rarely detected in early stages of vulvar squamous carcinomas (tumors less than 2 cm, clinical stage I) regardless of the tumor grade. In larger and more advanced tumors (greater than 2 cm, clinical stages II and III), CK10 is detected very frequently. Expression of CK10 is related to maturation of malignant keratinocytes, being preferentially detected in more-differentiated parts.

Description: This mAb recognizes a protein of 56.5kDa, identified as cytokeratin 10 (CK10). CK10 is expressed in all suprabasal layers of the epidermis. In the epidermis, expression of CK10 strictly parallels the extent of differentiation; it is absent in the basal layer, appears in the first suprabasal layers and increases in concentration towards the granular layer. However, CK10 is rarely detected in early stages of vulvar squamous carcinomas (tumors less than 2 cm, clinical stage I) regardless of the tumor grade. In larger and more advanced tumors (greater than 2 cm, clinical stages II and III), CK10 is detected very frequently. Expression of CK10 is related to maturation of malignant keratinocytes, being preferentially detected in more-differentiated parts.

Description: This mAb recognizes a protein of 56.5kDa, identified as cytokeratin 10 (CK10). CK10 is expressed in all suprabasal layers of the epidermis. In the epidermis, expression of CK10 strictly parallels the extent of differentiation; it is absent in the basal layer, appears in the first suprabasal layers and increases in concentration towards the granular layer. However, CK10 is rarely detected in early stages of vulvar squamous carcinomas (tumors less than 2 cm, clinical stage I) regardless of the tumor grade. In larger and more advanced tumors (greater than 2 cm, clinical stages II and III), CK10 is detected very frequently. Expression of CK10 is related to maturation of malignant keratinocytes, being preferentially detected in more-differentiated parts.

Description: This mAb recognizes a protein of 56.5kDa, identified as cytokeratin 10 (CK10). CK10 is expressed in all suprabasal layers of the epidermis. In the epidermis, expression of CK10 strictly parallels the extent of differentiation; it is absent in the basal layer, appears in the first suprabasal layers and increases in concentration towards the granular layer. However, CK10 is rarely detected in early stages of vulvar squamous carcinomas (tumors less than 2 cm, clinical stage I) regardless of the tumor grade. In larger and more advanced tumors (greater than 2 cm, clinical stages II and III), CK10 is detected very frequently. Expression of CK10 is related to maturation of malignant keratinocytes, being preferentially detected in more-differentiated parts.

Description: This mAb recognizes a protein of 56.5kDa, identified as cytokeratin 10 (CK10). CK10 is expressed in all suprabasal layers of the epidermis. In the epidermis, expression of CK10 strictly parallels the extent of differentiation; it is absent in the basal layer, appears in the first suprabasal layers and increases in concentration towards the granular layer. However, CK10 is rarely detected in early stages of vulvar squamous carcinomas (tumors less than 2 cm, clinical stage I) regardless of the tumor grade. In larger and more advanced tumors (greater than 2 cm, clinical stages II and III), CK10 is detected very frequently. Expression of CK10 is related to maturation of malignant keratinocytes, being preferentially detected in more-differentiated parts.

Description: This mAb recognizes a protein of 56.5kDa, identified as cytokeratin 10 (CK10). CK10 is expressed in all suprabasal layers of the epidermis. In the epidermis, expression of CK10 strictly parallels the extent of differentiation; it is absent in the basal layer, appears in the first suprabasal layers and increases in concentration towards the granular layer. However, CK10 is rarely detected in early stages of vulvar squamous carcinomas (tumors less than 2 cm, clinical stage I) regardless of the tumor grade. In larger and more advanced tumors (greater than 2 cm, clinical stages II and III), CK10 is detected very frequently. Expression of CK10 is related to maturation of malignant keratinocytes, being preferentially detected in more-differentiated parts.

Description: This mAb recognizes a protein of 56.5kDa, identified as cytokeratin 10 (CK10). CK10 is expressed in all suprabasal layers of the epidermis. In the epidermis, expression of CK10 strictly parallels the extent of differentiation; it is absent in the basal layer, appears in the first suprabasal layers and increases in concentration towards the granular layer. However, CK10 is rarely detected in early stages of vulvar squamous carcinomas (tumors less than 2 cm, clinical stage I) regardless of the tumor grade. In larger and more advanced tumors (greater than 2 cm, clinical stages II and III), CK10 is detected very frequently. Expression of CK10 is related to maturation of malignant keratinocytes, being preferentially detected in more-differentiated parts.

Description: This mAb recognizes a protein of 56.5kDa, identified as cytokeratin 10 (KRT10). KRT10 is expressed in all suprabasal layers of the epidermis. In the epidermis, expression of KRT10 strictly parallels the extent of differentiation; it is absent in the basal layer, appears in the first suprabasal layers and increases in concentration towards the granular layer. However, KRT10 is rarely detected in early stages of vulvar squamous carcinomas (tumors less than 2 cm, clinical stage I) regardless of the tumor grade. In larger and more advanced tumors (greater than 2 cm, clinical stages II and III), KRT10 is detected very frequently. Expression is related to maturation of malignant keratinocytes, being preferentially detected in more-differentiated parts.

Description: This mAb recognizes a protein of 56.5kDa, identified as cytokeratin 10 (KRT10). KRT10 is expressed in all suprabasal layers of the epidermis. In the epidermis, expression of KRT10 strictly parallels the extent of differentiation; it is absent in the basal layer, appears in the first suprabasal layers and increases in concentration towards the granular layer. However, KRT10 is rarely detected in early stages of vulvar squamous carcinomas (tumors less than 2 cm, clinical stage I) regardless of the tumor grade. In larger and more advanced tumors (greater than 2 cm, clinical stages II and III), KRT10 is detected very frequently. Expression is related to maturation of malignant keratinocytes, being preferentially detected in more-differentiated parts.

Description: This mAb recognizes a protein of 56.5kDa, identified as cytokeratin 10 (KRT10). KRT10 is expressed in all suprabasal layers of the epidermis. In the epidermis, expression of KRT10 strictly parallels the extent of differentiation; it is absent in the basal layer, appears in the first suprabasal layers and increases in concentration towards the granular layer. However, KRT10 is rarely detected in early stages of vulvar squamous carcinomas (tumors less than 2 cm, clinical stage I) regardless of the tumor grade. In larger and more advanced tumors (greater than 2 cm, clinical stages II and III), KRT10 is detected very frequently. Expression is related to maturation of malignant keratinocytes, being preferentially detected in more-differentiated parts.

Description: This mAb recognizes a protein of 56.5kDa, identified as cytokeratin 10 (KRT10). KRT10 is expressed in all suprabasal layers of the epidermis. In the epidermis, expression of KRT10 strictly parallels the extent of differentiation; it is absent in the basal layer, appears in the first suprabasal layers and increases in concentration towards the granular layer. However, KRT10 is rarely detected in early stages of vulvar squamous carcinomas (tumors less than 2 cm, clinical stage I) regardless of the tumor grade. In larger and more advanced tumors (greater than 2 cm, clinical stages II and III), KRT10 is detected very frequently. Expression is related to maturation of malignant keratinocytes, being preferentially detected in more-differentiated parts.

Description: This mAb recognizes a protein of 56.5kDa, identified as cytokeratin 10 (CK10). CK10 is expressed in all suprabasal layers of the epidermis. In the epidermis, expression of CK10 strictly parallels the extent of differentiation; it is absent in the basal layer, appears in the first suprabasal layers and increases in concentration towards the granular layer. However, CK10 is rarely detected in early stages of vulvar squamous carcinomas (tumors less than 2 cm, clinical stage I) regardless of the tumor grade. In larger and more advanced tumors (greater than 2 cm, clinical stages II and III), CK10 is detected very frequently. Expression of CK10 is related to maturation of malignant keratinocytes, being preferentially detected in more-differentiated parts.

Description: This mAb recognizes a protein of 56.5kDa, identified as cytokeratin 10 (CK10). CK10 is expressed in all suprabasal layers of the epidermis. In the epidermis, expression of CK10 strictly parallels the extent of differentiation; it is absent in the basal layer, appears in the first suprabasal layers and increases in concentration towards the granular layer. However, CK10 is rarely detected in early stages of vulvar squamous carcinomas (tumors less than 2 cm, clinical stage I) regardless of the tumor grade. In larger and more advanced tumors (greater than 2 cm, clinical stages II and III), CK10 is detected very frequently. Expression of CK10 is related to maturation of malignant keratinocytes, being preferentially detected in more-differentiated parts.

Description: This mAb recognizes a protein of 56.5kDa, identified as cytokeratin 10 (CK10). CK10 is expressed in all suprabasal layers of the epidermis. In the epidermis, expression of CK10 strictly parallels the extent of differentiation; it is absent in the basal layer, appears in the first suprabasal layers and increases in concentration towards the granular layer. However, CK10 is rarely detected in early stages of vulvar squamous carcinomas (tumors less than 2 cm, clinical stage I) regardless of the tumor grade. In larger and more advanced tumors (greater than 2 cm, clinical stages II and III), CK10 is detected very frequently. Expression of CK10 is related to maturation of malignant keratinocytes, being preferentially detected in more-differentiated parts.

Description: This mAb recognizes a protein of 56.5kDa, identified as cytokeratin 10 (CK10). CK10 is expressed in all suprabasal layers of the epidermis. In the epidermis, expression of CK10 strictly parallels the extent of differentiation; it is absent in the basal layer, appears in the first suprabasal layers and increases in concentration towards the granular layer. However, CK10 is rarely detected in early stages of vulvar squamous carcinomas (tumors less than 2 cm, clinical stage I) regardless of the tumor grade. In larger and more advanced tumors (greater than 2 cm, clinical stages II and III), CK10 is detected very frequently. Expression of CK10 is related to maturation of malignant keratinocytes, being preferentially detected in more-differentiated parts.

Description: This mAb recognizes a protein of 56.5kDa, identified as cytokeratin 10 (CK10). CK10 is expressed in all suprabasal layers of the epidermis. In the epidermis, expression of CK10 strictly parallels the extent of differentiation; it is absent in the basal layer, appears in the first suprabasal layers and increases in concentration towards the granular layer. However, CK10 is rarely detected in early stages of vulvar squamous carcinomas (tumors less than 2 cm, clinical stage I) regardless of the tumor grade. In larger and more advanced tumors (greater than 2 cm, clinical stages II and III), CK10 is detected very frequently. Expression of CK10 is related to maturation of malignant keratinocytes, being preferentially detected in more-differentiated parts.

Description: This mAb recognizes a protein of 56.5kDa, identified as cytokeratin 10 (CK10). CK10 is expressed in all suprabasal layers of the epidermis. In the epidermis, expression of CK10 strictly parallels the extent of differentiation; it is absent in the basal layer, appears in the first suprabasal layers and increases in concentration towards the granular layer. However, CK10 is rarely detected in early stages of vulvar squamous carcinomas (tumors less than 2 cm, clinical stage I) regardless of the tumor grade. In larger and more advanced tumors (greater than 2 cm, clinical stages II and III), CK10 is detected very frequently. Expression of CK10 is related to maturation of malignant keratinocytes, being preferentially detected in more-differentiated parts.

Description: This mAb recognizes a protein of 56.5kDa, identified as cytokeratin 10 (CK10). CK10 is expressed in all suprabasal layers of the epidermis. In the epidermis, expression of CK10 strictly parallels the extent of differentiation; it is absent in the basal layer, appears in the first suprabasal layers and increases in concentration towards the granular layer. However, CK10 is rarely detected in early stages of vulvar squamous carcinomas (tumors less than 2 cm, clinical stage I) regardless of the tumor grade. In larger and more advanced tumors (greater than 2 cm, clinical stages II and III), CK10 is detected very frequently. Expression of CK10 is related to maturation of malignant keratinocytes, being preferentially detected in more-differentiated parts.

Description: This mAb recognizes a protein of 56.5kDa, identified as cytokeratin 10 (CK10). CK10 is expressed in all suprabasal layers of the epidermis. In the epidermis, expression of CK10 strictly parallels the extent of differentiation; it is absent in the basal layer, appears in the first suprabasal layers and increases in concentration towards the granular layer. However, CK10 is rarely detected in early stages of vulvar squamous carcinomas (tumors less than 2 cm, clinical stage I) regardless of the tumor grade. In larger and more advanced tumors (greater than 2 cm, clinical stages II and III), CK10 is detected very frequently. Expression of CK10 is related to maturation of malignant keratinocytes, being preferentially detected in more-differentiated parts.

Description: Cytokeratin-10 (CK-10) or keratin-10 (K10) is a protein that in humans is encoded by the KRT10 gene. CK10 is a member of the type I (acidic) cytokeratin family, which belongs to the superfamily of intermediate filament (IF) proteins. Keratins are heteropolymeric structural proteins which form the intermediate filament. These filaments, along with actin microfilaments and microtubules, compose the cytoskeleton of epithelial cells. Mutations in this gene are associated with epidermolytic hyperkeratosis. [Wiki]

Description: Cytokeratin-10 (CK-10) or keratin-10 (K10) is a protein that in humans is encoded by the KRT10 gene. CK10 is a member of the type I (acidic) cytokeratin family, which belongs to the superfamily of intermediate filament (IF) proteins. Keratins are heteropolymeric structural proteins which form the intermediate filament. These filaments, along with actin microfilaments and microtubules, compose the cytoskeleton of epithelial cells. Mutations in this gene are associated with epidermolytic hyperkeratosis. [Wiki]

Description: Cytokeratin-10 (CK-10) or keratin-10 (K10) is a protein that in humans is encoded by the KRT10 gene. CK10 is a member of the type I (acidic) cytokeratin family, which belongs to the superfamily of intermediate filament (IF) proteins. Keratins are heteropolymeric structural proteins which form the intermediate filament. These filaments, along with actin microfilaments and microtubules, compose the cytoskeleton of epithelial cells. Mutations in this gene are associated with epidermolytic hyperkeratosis. [Wiki]

Description: Cytokeratin-10 (CK-10) or keratin-10 (K10) is a protein that in humans is encoded by the KRT10 gene. CK10 is a member of the type I (acidic) cytokeratin family, which belongs to the superfamily of intermediate filament (IF) proteins. Keratins are heteropolymeric structural proteins which form the intermediate filament. These filaments, along with actin microfilaments and microtubules, compose the cytoskeleton of epithelial cells. Mutations in this gene are associated with epidermolytic hyperkeratosis. [Wiki]

Description: Keratin-10 is a member of the type I (acidic) cytokeratin family, which belongs to the superfamily of intermediate filament (IF) proteins. Keratins are heteropolymeric structural proteins which form the intermediate filament. These filaments, along with actin microfilaments and microtubules, compose the cytoskeleton of epithelial cells. Mutations in this gene are associated with epidermolytic hyperkeratosis. This gene is located within a cluster of keratin family members on chromosome 17q21. Keratin 10 has been shown to interact with AKT1. [Wiki]

Description: Keratin-10 is a member of the type I (acidic) cytokeratin family, which belongs to the superfamily of intermediate filament (IF) proteins. Keratins are heteropolymeric structural proteins which form the intermediate filament. These filaments, along with actin microfilaments and microtubules, compose the cytoskeleton of epithelial cells. Mutations in this gene are associated with epidermolytic hyperkeratosis. This gene is located within a cluster of keratin family members on chromosome 17q21. Keratin 10 has been shown to interact with AKT1. [Wiki]

Description: Keratin-10 is a member of the type I (acidic) cytokeratin family, which belongs to the superfamily of intermediate filament (IF) proteins. Keratins are heteropolymeric structural proteins which form the intermediate filament. These filaments, along with actin microfilaments and microtubules, compose the cytoskeleton of epithelial cells. Mutations in this gene are associated with epidermolytic hyperkeratosis. This gene is located within a cluster of keratin family members on chromosome 17q21. Keratin 10 has been shown to interact with AKT1. [Wiki]

Description: Keratin-10 is a member of the type I (acidic) cytokeratin family, which belongs to the superfamily of intermediate filament (IF) proteins. Keratins are heteropolymeric structural proteins which form the intermediate filament. These filaments, along with actin microfilaments and microtubules, compose the cytoskeleton of epithelial cells. Mutations in this gene are associated with epidermolytic hyperkeratosis. This gene is located within a cluster of keratin family members on chromosome 17q21. Keratin 10 has been shown to interact with AKT1. [Wiki]

Description: This antibody recognizes a protein of 56.5kDa, identified as cytokeratin 10 (CK10). cytokeratin 10 is expressed in all suprabasal layers of the epidermis. In the epidermis, expression of cytokeratin 10 strictly parallels the extent of differentiation; it is absent in the basal layer, appears in the first suprabasal layers and increases in concentration towards the granular layer. However, cytokeratin 10 is rarely detected in early stages of vulvar squamous carcinomas (tumors less than 2 cm, clinical stage I) regardless of the tumor grade. In larger and more advanced tumors (greater than 2 cm, clinical stages II and III), cytokeratin 10 is detected very frequently. Expression of cytokeratin 10 is related to maturation of malignant keratinocytes, being preferentially detected in more-differentiated parts.

Description: This antibody recognizes a protein of 56.5kDa, identified as cytokeratin 10 (CK10). cytokeratin 10 is expressed in all suprabasal layers of the epidermis. In the epidermis, expression of cytokeratin 10 strictly parallels the extent of differentiation; it is absent in the basal layer, appears in the first suprabasal layers and increases in concentration towards the granular layer. However, cytokeratin 10 is rarely detected in early stages of vulvar squamous carcinomas (tumors less than 2 cm, clinical stage I) regardless of the tumor grade. In larger and more advanced tumors (greater than 2 cm, clinical stages II and III), cytokeratin 10 is detected very frequently. Expression of cytokeratin 10 is related to maturation of malignant keratinocytes, being preferentially detected in more-differentiated parts.

Description: This antibody recognizes a protein of 56.5kDa, identified as cytokeratin 10 (CK10). cytokeratin 10 is expressed in all suprabasal layers of the epidermis. In the epidermis, expression of cytokeratin 10 strictly parallels the extent of differentiation; it is absent in the basal layer, appears in the first suprabasal layers and increases in concentration towards the granular layer. However, cytokeratin 10 is rarely detected in early stages of vulvar squamous carcinomas (tumors less than 2 cm, clinical stage I) regardless of the tumor grade. In larger and more advanced tumors (greater than 2 cm, clinical stages II and III), cytokeratin 10 is detected very frequently. Expression of cytokeratin 10 is related to maturation of malignant keratinocytes, being preferentially detected in more-differentiated parts.

Description: This antibody recognizes a protein of 56.5kDa, identified as cytokeratin 10 (CK10). cytokeratin 10 is expressed in all suprabasal layers of the epidermis. In the epidermis, expression of cytokeratin 10 strictly parallels the extent of differentiation; it is absent in the basal layer, appears in the first suprabasal layers and increases in concentration towards the granular layer. However, cytokeratin 10 is rarely detected in early stages of vulvar squamous carcinomas (tumors less than 2 cm, clinical stage I) regardless of the tumor grade. In larger and more advanced tumors (greater than 2 cm, clinical stages II and III), cytokeratin 10 is detected very frequently. Expression of cytokeratin 10 is related to maturation of malignant keratinocytes, being preferentially detected in more-differentiated parts.

Description: This MAb recognizes a protein of 56.5kDa, identified as cytokeratin 10 (CK10). CK10 is expressed in all suprabasal layers of the epidermis. In the epidermis, expression of CK10 strictly parallels the extent of differentiation; it is absent in the basal layer, appears in the first suprabasal layers and increases in concentration towards the granular layer. However, CK10 is rarely detected in early stages of vulvar squamous carcinomas (tumors less than 2 cm, clinical stage I) regardless of the tumor grade. In larger and more advanced tumors (greater than 2 cm, clinical stages II and III), CK10 is detected very frequently. Expression of CK10 is related to maturation of malignant keratinocytes, being preferentially detected in more-differentiated parts.

Description: This MAb recognizes a protein of 56.5kDa, identified as cytokeratin 10 (CK10). CK10 is expressed in all suprabasal layers of the epidermis. In the epidermis, expression of CK10 strictly parallels the extent of differentiation; it is absent in the basal layer, appears in the first suprabasal layers and increases in concentration towards the granular layer. However, CK10 is rarely detected in early stages of vulvar squamous carcinomas (tumors less than 2 cm, clinical stage I) regardless of the tumor grade. In larger and more advanced tumors (greater than 2 cm, clinical stages II and III), CK10 is detected very frequently. Expression of CK10 is related to maturation of malignant keratinocytes, being preferentially detected in more-differentiated parts.

Description: This MAb recognizes a protein of 56.5kDa, identified as cytokeratin 10 (CK10). CK10 is expressed in all suprabasal layers of the epidermis. In the epidermis, expression of CK10 strictly parallels the extent of differentiation; it is absent in the basal layer, appears in the first suprabasal layers and increases in concentration towards the granular layer. However, CK10 is rarely detected in early stages of vulvar squamous carcinomas (tumors less than 2 cm, clinical stage I) regardless of the tumor grade. In larger and more advanced tumors (greater than 2 cm, clinical stages II and III), CK10 is detected very frequently. Expression of CK10 is related to maturation of malignant keratinocytes, being preferentially detected in more-differentiated parts.

Description: Rabbit polyclonal Keratin 10 antibody

Description: Primary antibody against Cytokeratin 10(KRT10/844), CF405S conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 10(KRT10/844), CF405S conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 10(KRT10/844), CF405M conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 10(KRT10/844), CF405M conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 10(KRT10/844), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 10(KRT10/844), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 10(KRT10/844), Biotin conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 10(KRT10/844), Biotin conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 10(KRT10/844), PerCP conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 10(KRT10/844), RPE conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 10(KRT10/844), CF594 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 10(KRT10/844), CF594 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 10(KRT10/844), APC conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 10(KRT10/844), CF680R conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 10(KRT10/844), CF680R conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 10(KRT10/844), Concentration: 0.2mg/mL

Description: Primary antibody against Cytokeratin 10(KRT10/844), Concentration: 0.2mg/mL

Description: Primary antibody against Cytokeratin 10(KRT10/844), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 10(KRT10/844), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 10(KRT10/844), CF488A conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 10(KRT10/844), CF488A conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 10(KRT10/844), CF568 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 10(KRT10/844), CF568 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 10(KRT10/844), CF647 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 10(KRT10/844), CF647 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 10(KRT10/844), CF640R conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 10(KRT10/844), CF640R conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 10(KRT10/844), CF543 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 10(KRT10/844), CF543 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 10(KRT10/844), CF555 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 10(KRT10/844), CF555 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 10(KRT10/844), CF660R conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 10(KRT10/844), CF660R conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 10(KRT10/844), CF680 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 10(KRT10/844), CF680 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 10(KRT10/844), CF770 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 10(KRT10/844), CF770 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 10(KRT10/844), 1mg/mL

Description: This mAb cocktail recognizes a protein of 56.5kDa, identified as cytokeratin 10 (CK10). CK10 is expressed in all suprabasal layers of the epidermis. In the epidermis, expression of CK10 strictly parallels the extent of differentiation; it is absent in the basal layer, appears in the first suprabasal layers and increases in concentration towards the granular layer. However, CK10 is rarely detected in early stages of vulvar squamous carcinomas (tumors less than 2 cm, clinical stage I) regardless of the tumor grade. In larger and more advanced tumors (greater than 2 cm, clinical stages II and III), CK10 is detected very frequently. Expression of CK10 is related to maturation of malignant keratinocytes, being preferentially detected in more-differentiated parts.

Description: This mAb cocktail recognizes a protein of 56.5kDa, identified as cytokeratin 10 (CK10). CK10 is expressed in all suprabasal layers of the epidermis. In the epidermis, expression of CK10 strictly parallels the extent of differentiation; it is absent in the basal layer, appears in the first suprabasal layers and increases in concentration towards the granular layer. However, CK10 is rarely detected in early stages of vulvar squamous carcinomas (tumors less than 2 cm, clinical stage I) regardless of the tumor grade. In larger and more advanced tumors (greater than 2 cm, clinical stages II and III), CK10 is detected very frequently. Expression of CK10 is related to maturation of malignant keratinocytes, being preferentially detected in more-differentiated parts.

Description: This mAb cocktail recognizes a protein of 56.5kDa, identified as cytokeratin 10 (CK10). CK10 is expressed in all suprabasal layers of the epidermis. In the epidermis, expression of CK10 strictly parallels the extent of differentiation; it is absent in the basal layer, appears in the first suprabasal layers and increases in concentration towards the granular layer. However, CK10 is rarely detected in early stages of vulvar squamous carcinomas (tumors less than 2 cm, clinical stage I) regardless of the tumor grade. In larger and more advanced tumors (greater than 2 cm, clinical stages II and III), CK10 is detected very frequently. Expression of CK10 is related to maturation of malignant keratinocytes, being preferentially detected in more-differentiated parts.

Description: Primary antibody against Cytokeratin 10 (KRT10) (Suprabasal Epithelial Marker) (KRT10/1990R), CF405S conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 10 (KRT10) (Suprabasal Epithelial Marker) (KRT10/1990R), CF405S conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 10 (KRT10) (Suprabasal Epithelial Marker) (KRT10/1990R), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 10 (KRT10) (Suprabasal Epithelial Marker) (KRT10/1990R), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 10 (KRT10) (Suprabasal Epithelial Marker) (KRT10/1990R), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 10 (KRT10) (Suprabasal Epithelial Marker) (KRT10/1990R), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 10 (KRT10) (Suprabasal Epithelial Marker) (KRT10/1990R), PerCP conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 10 (KRT10) (Suprabasal Epithelial Marker) (KRT10/1990R), RPE conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 10 (KRT10) (Suprabasal Epithelial Marker) (KRT10/1990R), CF594 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 10 (KRT10) (Suprabasal Epithelial Marker) (KRT10/1990R), CF594 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 10 (KRT10) (Suprabasal Epithelial Marker) (KRT10/1990R), APC conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 10 (KRT10) (Suprabasal Epithelial Marker) (KRT10/1990R), CF680R conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 10 (KRT10) (Suprabasal Epithelial Marker) (KRT10/1990R), CF680R conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 10 (KRT10) (Suprabasal Epithelial Marker) (KRT10/1990R), Concentration: 0.2mg/mL

Description: Primary antibody against Cytokeratin 10 (KRT10) (Suprabasal Epithelial Marker) (KRT10/1990R), 1mg/mL

Description: Primary antibody against Cytokeratin 10 (KRT10) (Suprabasal Epithelial Marker) (KRT10/1990R), Concentration: 0.2mg/mL

Description: Primary antibody against Cytokeratin 10 (KRT10) (Suprabasal Epithelial Marker) (KRT10/1990R), CF488A conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 10 (KRT10) (Suprabasal Epithelial Marker) (KRT10/1990R), CF488A conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 10 (KRT10) (Suprabasal Epithelial Marker) (KRT10/1990R), Biotin conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 10 (KRT10) (Suprabasal Epithelial Marker) (KRT10/1990R), Biotin conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 10 (KRT10) (Suprabasal Epithelial Marker) (KRT10/1990R), CF660R conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 10 (KRT10) (Suprabasal Epithelial Marker) (KRT10/1990R), CF660R conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 10 (KRT10) (Suprabasal Epithelial Marker) (KRT10/1990R), CF568 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 10 (KRT10) (Suprabasal Epithelial Marker) (KRT10/1990R), CF568 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 10 (KRT10) (Suprabasal Epithelial Marker) (KRT10/1990R), CF543 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 10 (KRT10) (Suprabasal Epithelial Marker) (KRT10/1990R), CF543 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 10 (KRT10) (Suprabasal Epithelial Marker) (KRT10/1990R), CF647 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 10 (KRT10) (Suprabasal Epithelial Marker) (KRT10/1990R), CF647 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 10 (KRT10) (Suprabasal Epithelial Marker) (KRT10/1990R), CF640R conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 10 (KRT10) (Suprabasal Epithelial Marker) (KRT10/1990R), CF640R conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 10 (KRT10) (Suprabasal Epithelial Marker) (KRT10/1990R), CF555 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 10 (KRT10) (Suprabasal Epithelial Marker) (KRT10/1990R), CF555 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 10 (KRT10) (Suprabasal Epithelial Marker) (KRT10/1990R), CF680 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 10 (KRT10) (Suprabasal Epithelial Marker) (KRT10/1990R), CF680 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 10 (KRT10) (Suprabasal Epithelial Marker) (KRT10/1990R), CF405M conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 10 (KRT10) (Suprabasal Epithelial Marker) (KRT10/1990R), CF405M conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 10 (KRT10) (Suprabasal Epithelial Marker) (KRT10/1990R), CF770 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 10 (KRT10) (Suprabasal Epithelial Marker) (KRT10/1990R), CF770 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 10 (Suprabasal Epithelial Marker) (KRT10/844 + KRT10/1275),CF405S conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 10 (Suprabasal Epithelial Marker) (KRT10/844 + KRT10/1275),CF405S conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 10 (Suprabasal Epithelial Marker) (KRT10/844 + KRT10/1275),Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 10 (Suprabasal Epithelial Marker) (KRT10/844 + KRT10/1275),Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 10 (Suprabasal Epithelial Marker) (KRT10/844 + KRT10/1275),PerCP conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 10 (Suprabasal Epithelial Marker) (KRT10/844 + KRT10/1275),RPE conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 10 (Suprabasal Epithelial Marker) (KRT10/844 + KRT10/1275),CF594 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 10 (Suprabasal Epithelial Marker) (KRT10/844 + KRT10/1275),CF594 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 10 (Suprabasal Epithelial Marker) (KRT10/844 + KRT10/1275),APC conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 10 (Suprabasal Epithelial Marker) (KRT10/844 + KRT10/1275),CF680R conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 10 (Suprabasal Epithelial Marker) (KRT10/844 + KRT10/1275),CF680R conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 10 (Suprabasal Epithelial Marker) (KRT10/844 + KRT10/1275), Concentration: 0.2mg/mL

Description: Primary antibody against Cytokeratin 10 (Suprabasal Epithelial Marker) (KRT10/844 + KRT10/1275), Concentration: 0.2mg/mL

Description: Primary antibody against Cytokeratin 10 (Suprabasal Epithelial Marker) (KRT10/844 + KRT10/1275),Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 10 (Suprabasal Epithelial Marker) (KRT10/844 + KRT10/1275),Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 10 (Suprabasal Epithelial Marker) (KRT10/844 + KRT10/1275),CF488A conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 10 (Suprabasal Epithelial Marker) (KRT10/844 + KRT10/1275),CF488A conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 10 (Suprabasal Epithelial Marker) (KRT10/844 + KRT10/1275),Biotin conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 10 (Suprabasal Epithelial Marker) (KRT10/844 + KRT10/1275),Biotin conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 10 (Suprabasal Epithelial Marker) (KRT10/844 + KRT10/1275),CF660R conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 10 (Suprabasal Epithelial Marker) (KRT10/844 + KRT10/1275),CF660R conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 10 (Suprabasal Epithelial Marker) (KRT10/844 + KRT10/1275),CF568 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 10 (Suprabasal Epithelial Marker) (KRT10/844 + KRT10/1275),CF568 conjugate, Concentration: 0.1mg/mL